Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Short-term Investments (2020 - 2025)

Silence Therapeutics (SLN) has disclosed Short-term Investments for 4 consecutive years, with $73.8 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments rose 183.94% to $73.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $73.8 million through Dec 2025, up 183.94% year-over-year, with the annual reading at $73.8 million for FY2025, 183.94% up from the prior year.
  • Short-term Investments hit $73.8 million in Q4 2025 for Silence Therapeutics, up from $20.2 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $73.8 million in Q4 2025 to a low of $20.2 million in Q3 2025.
  • Historically, Short-term Investments has averaged $50.2 million across 3 years, with a median of $54.3 million in 2023.
  • Biggest five-year swings in Short-term Investments: fell 29.66% in 2024 and later surged 183.94% in 2025.
  • Year by year, Short-term Investments stood at $37.0 million in 2023, then dropped by 29.66% to $26.0 million in 2024, then soared by 183.94% to $73.8 million in 2025.
  • Business Quant data shows Short-term Investments for SLN at $73.8 million in Q4 2025, $20.2 million in Q3 2025, and $72.4 million in Q2 2025.